XORTX Therapeutics Inc. - SIC # 2830 -

Ticker Exchange SIC # Website Latest Ticker
XRTX Nasdaq 2830 www.xortx.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for XORTX Therapeutics Inc.

XORTX Outlines Anticipated Health Canada Clinical Trial Application for XRx-026 for Gout - Oct 8th, 2026 2:00 pm
XORTX Announces Planned FDA IND Submission for XRx-026 Gout Program Using XORLO™, Targeting USD$700M+ U.S. Gout Market Opportunity - Sep 18th, 2026 6:05 am
XORTX Announces Initiation of Clinical and Commercial Manufacturing of XORLO™ - Sep 10th, 2026 2:05 pm
XORTX Re-Engages Investor Relations Program - Sep 8th, 2026 4:15 pm
XORTX Announces Termination and Postponement of Investor Relations Program - Aug 28th, 2026 5:00 am
XORTX Announces Director Resignation - Jul 31st, 2026 3:00 pm
XORTX Appoints New Director - Jul 29th, 2026 5:00 am
XORTX Provides Corporate Update and Announces Appointment of Mika Grasso as Co-CEO - Jun 15th, 2026 5:00 am
XORTX Announces Election to Voluntary Delist from the TSX Venture Exchange - Jun 12th, 2026 3:00 pm
XORTX Announces Closing of US$5 Million Public Offering - May 19th, 2026 5:00 am
E.F. Hutton & Co. Serves as Exclusive Placement Agent on XORTX Therapeutics Inc. $5 Million Public Offering - May 18th, 2026 9:20 am
XORTX Announces US$5 Million Public Offering - May 14th, 2026 5:00 am
XORTX Meets Nasdaq Continued Listing Requirements - Apr 21st, 2026 5:00 am
XORTX Announces Closing of Acquisition of Vectus Kidney Anti-fibrotic Asset - Apr 13th, 2026 3:00 pm
XORTX Provides Update on Acquisition of Renal Anti-Fibrotic Therapeutic Program from Vectus Biosystems - Feb 4th, 2026 4:00 pm